Disclosures for "Sensitivity of Digital Clinical Biomarker Endpoints to Detect Disease Progression during the 8-week Pretreatment Run-In Period in Proof-of-Concept ALS Study VGCS-50635-002 "
-
Dr. Cadavid has received personal compensation for serving as an employee of Verge Genomics. Dr. Cadavid has received personal compensation for serving as an employee of X4 Pharmaceuticals. Dr. Cadavid has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Pheno Therapeutics. Dr. Cadavid has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novo Nordisk. Dr. Cadavid has stock in Verge Genomics.
-
Prof. Katabi has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for J&J. Prof. Katabi has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amgen. Prof. Katabi has received personal compensation in the range of $50,000-$99,999 for serving as an officer or member of the Board of Directors for Cyclerion, Inc. Prof. Katabi has stock in Emerald Innovations, Inc.. The institution of Prof. Katabi has received research support from Michael J Fox Foundation. The institution of Prof. Katabi has received research support from Rett Syndrome Research Trust. The institution of Prof. Katabi has received research support from Wistron. The institution of Prof. Katabi has received research support from Takeda. The institution of Prof. Katabi has received research support from Gwangju Institute of Science and Technology. The institution of Prof. Katabi has received research support from KACST . The institution of Prof. Katabi has received research support from IBM.
-
Dr. Hoffmann has received personal compensation for serving as an employee of Xencor. Dr. Hoffmann has received personal compensation for serving as an employee of Verge Genomics. Dr. Hoffmann has stock in Xencor.
-
Author has nothing to disclose
-
Dr. Tarachandani has received personal compensation for serving as an employee of Verge Genomics. Dr. Tarachandani has stock in Verge Genomics.
-
Dr. Choi has received personal compensation for serving as an employee of Verge Genomics. Dr. Choi has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Modality AI. Dr. Choi has stock in Nektar Therapeutics. Dr. Choi has stock in Verge Genomics. Dr. Choi has stock in Modality AI.
-
Author has nothing to disclose
-
Dr. Swami has nothing to disclose.
-
Joanna Haas has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for Vergegenomics . Joanna Haas has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for Nimbus Therapeutics . Joanna Haas has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for X4 Pharmaceuticals.
-
Dr. Schmidt has received personal compensation for serving as an employee of Kypha Inc.. Dr. Schmidt has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Verge Genomics. Dr. Schmidt has stock in Kypha Inc. Dr. Schmidt has received intellectual property interests from a discovery or technology relating to health care.
-
Dr. Tracewell has received personal compensation for serving as an employee of Allucent.
-
Author has nothing to disclose
-
Shane Raines has received personal compensation for serving as an employee of Praxis Precision Medicines. Shane Raines has received personal compensation for serving as an employee of 2b Analytics.
-
Dr. Shook has nothing to disclose.
-
Mr. Hristov has received personal compensation for serving as an employee of Emerald Innovations. Mr. Hristov has stock in Emerald Innovations.
-
Mr. Krishna has received personal compensation for serving as an employee of Emerald Innovations. Mr. Krishna has stock in Emerald Innovations.
-
Ms. Levy has stock in Emerald Innovations.
-
Author has nothing to disclose
-
Dr. Yue has received personal compensation for serving as an employee of Emerald Innovation, Inc.
-
Dr. Kothare has received personal compensation for serving as an employee of Modality.AI, Inc.. Dr. Kothare has stock in Modality.AI, Inc..
-
Dr. Neumann has received personal compensation for serving as an employee of Modality.AI. Dr. Neumann has stock in Modality.AI.
-
Ms. Bartlett has received personal compensation for serving as an employee of Modality.AI.
-
Dr. Ramanarayanan has received personal compensation for serving as an employee of Modality.AI, Inc. . Dr. Ramanarayanan has received personal compensation in the range of $100,000-$499,999 for serving as an officer or member of the Board of Directors for Modality.AI, Inc. Dr. Ramanarayanan has stock in Modality.AI. The institution of Dr. Ramanarayanan has received research support from National Institutes of Health (NIH). Dr. Ramanarayanan has received personal compensation in the range of $500-$4,999 for serving as a Invited Speaker with American Speech and Hearing Association (ASHA).
-
The institution of Dr. Van Damme has received research support from CSL Behring.
-
Dr. Tienari has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck GmBH. Dr. Tienari has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Tienari has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Jansen. The institution of Dr. Tienari has received research support from Helsinki University Hospital. The institution of Dr. Tienari has received research support from Sigrid Juselius Foundation. The institution of Dr. Tienari has received research support from Maze Therapeutics. The institution of Dr. Tienari has received research support from Verge genomics. The institution of Dr. Tienari has received research support from University of Helsinki. The institution of Dr. Tienari has received research support from Private donor. Dr. Tienari has received intellectual property interests from a discovery or technology relating to health care.
-
Prof. Solje has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novo Nordisk. Prof. Solje has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Prof. Solje has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for EISAI. Prof. Solje has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Prof. Solje has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Lundbeck. Prof. Solje has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche.
-
Manu Jokela has nothing to disclose.
-
Dr. Genge has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for AL-S Pharma. Dr. Genge has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Amylyx. Dr. Genge has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for Quralis. Dr. Genge has received personal compensation in the range of $500-$4,999 for serving as a Consultant for MTPA. Dr. Genge has received personal compensation in the range of $0-$499 for serving as a Consultant for WAVE. Dr. Genge has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for eikonizo. Dr. Genge has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for pepgen. Dr. Genge has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for rapa.
-
Colleen O'Connell has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for MT Pharma. Colleen O'Connell has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Colleen O'Connell has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Colleen O'Connell has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for MT PHarma. The institution of Colleen O'Connell has received research support from Biogen. The institution of Colleen O'Connell has received research support from Calico. The institution of Colleen O'Connell has received research support from Praxis Spinal Cord Institute. The institution of Colleen O'Connell has received research support from Verge. Colleen O'Connell has a non-compensated relationship as a Steering Committee with World Rehabilitation Alliance that is relevant to AAN interests or activities.
-
Dr. van Eijk has nothing to disclose.
-
The institution of Dr. Van den Berg has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amylyx. The institution of Dr. Van den Berg has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for ferrrer. The institution of Dr. Van den Berg has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. The institution of Dr. Van den Berg has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. The institution of Dr. Van den Berg has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Takeda. The institution of Dr. Van den Berg has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. The institution of Dr. Van den Berg has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for BMS. The institution of Dr. Van den Berg has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for ArgenX. The institution of Dr. Van den Berg has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Projenx. The institution of Dr. Van den Berg has received research support from Netherlands ALS Foundation.